Evidence map›Paper›PMID 28122580›Full record

ArticleRetrovirology2017

Identification of small molecule modulators of HIV-1 Tat and Rev protein accumulation.

Ahalya Balachandran, Raymond Wong, Peter Stoilov, Sandy Pan, Benjamin Blencowe, Peter Cheung, P Richard Harrigan, Alan Cochrane

Open access · goldAbstract read
In one paragraph

Article in Retrovirology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Screening for gene expression fluctuations reveals latency-promoting agents of HIV.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Ahalya BalachandranDepartment of Molecular Genetics, University of Toronto, 1 King's College Circle, Toronto, ON, M5S1A8, Canada.
Raymond WongDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Peter StoilovDepartment of Biochemistry, University of West Virginia, Morgantown, WV, USA.
Sandy PanDonnelly Centre, University of Toronto, Toronto, ON, Canada.
Benjamin BlencoweDepartment of Molecular Genetics, University of Toronto, 1 King's College Circle, Toronto, ON, M5S1A8, Canada.
Peter CheungBritish Columbia Centre for Excellence in HIV/AIDS, 608-1081 Burrard St., Vancouver, BC, Canada.
P Richard HarriganBritish Columbia Centre for Excellence in HIV/AIDS, 608-1081 Burrard St., Vancouver, BC, Canada.
Alan CochraneDepartment of Molecular Genetics, University of Toronto, 1 King's College Circle, Toronto, ON, M5S1A8, Canada. alan.cochrane@utoronto.ca.
University of Toronto · CAAIDS Vancouver · CAWest Virginia University · US

Funding

CIHR HOP-134065
6 · The paper itself

Abstract

backgroundHIV-1 replication is critically dependent upon controlled processing of its RNA and the activities provided by its encoded regulatory factors Tat and Rev. A screen of small molecule modulators of RNA processing identified several which inhibited virus gene expression, affecting both relative abundance of specific HIV-1 RNAs and the levels of Tat and Rev proteins.

resultsThe screen for small molecules modulators of HIV-1 gene expression at the post-transcriptional level identified three (a pyrimidin-7-amine, biphenylcarboxamide, and benzohydrazide, designated 791, 833, and 892, respectively) that not only reduce expression of HIV-1 Gag and Env and alter the accumulation of viral RNAs, but also dramatically decrease Tat and Rev levels. Analyses of viral RNA levels by qRTPCR and RTPCR indicated that the loss of either protein could not be attributed to changes in abundance of the mRNAs encoding these factors. However, addition of the proteasome inhibitor MG132 did result in significant restoration of Tat expression, indicating that the compounds are affecting Tat synthesis and/or degradation. Tests in the context of replicating HIV-1 in PBMCs confirmed that 791 significantly reduced virus replication. Parallel analyses of the effect of the compounds on host gene expression revealed only minor changes in either mRNA abundance or alternative splicing. Subsequent tests suggest that 791 may function by reducing levels of the Tat/Rev chaperone Nap1.

conclusionsThe three compounds examined (791, 833, 892), despite their lack of structural similarity, all suppressed HIV-1 gene expression by preventing accumulation of two key HIV-1 regulatory factors, Tat and Rev. These findings demonstrate that selective disruption of HIV-1 gene expression can be achieved.

Indexed as

Anti-HIV AgentsCells, CulturedGene Expression Regulation, ViralHIV-1HumansModels, MolecularMolecular StructureReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain Reactionrev Gene Products, Human Immunodeficiency VirusRNA Processing, Post-TranscriptionalRNA, Viraltat Gene Products, Human Immunodeficiency VirusVirus ReplicationAnti-HIV Agentsrev Gene Products, Human Immunodeficiency Virusrev protein, Human Immunodeficiency Virus-1RNA, Viraltat Gene Products, Human Immunodeficiency VirusHIV-1RevRNA processingSmall molecule inhibitorsTat

Identifiers

PMID28122580
PMCPMC5267425
OpenAlexW2581184152

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.